Log in
NASDAQ:CRBP

Corbus Pharmaceuticals Stock Forecast, Price & News

$1.90
-0.06 (-3.06 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.75
Now: $1.90
$1.98
50-Day Range
$1.88
MA: $6.60
$9.38
52-Week Range
$1.75
Now: $1.90
$9.78
Volume33.02 million shs
Average Volume2.00 million shs
Market Capitalization$155.25 million
P/E RatioN/A
Dividend YieldN/A
Beta1.55
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.
Read More
Corbus Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.2Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.77 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRBP
CUSIPN/A
Phone617-963-0100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$36.14 million
Book Value$0.10 per share

Profitability

Net Income$-71,450,000.00
Net Margins-1,596.42%

Miscellaneous

Employees141
Market Cap$155.25 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$1.90
-0.06 (-3.06 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRBP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions

How has Corbus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Corbus Pharmaceuticals' stock was trading at $4.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRBP shares have decreased by 53.9% and is now trading at $1.90.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Corbus Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Corbus Pharmaceuticals
.

When is Corbus Pharmaceuticals' next earnings date?

Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Corbus Pharmaceuticals
.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) announced its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by $0.13. The biopharmaceutical company had revenue of $0.29 million for the quarter, compared to analysts' expectations of $3.90 million. Corbus Pharmaceuticals had a negative return on equity of 430.79% and a negative net margin of 1,596.42%.
View Corbus Pharmaceuticals' earnings history
.

What price target have analysts set for CRBP?

9 equities research analysts have issued 1 year price objectives for Corbus Pharmaceuticals' stock. Their forecasts range from $2.50 to $112.00. On average, they anticipate Corbus Pharmaceuticals' stock price to reach $26.72 in the next twelve months. This suggests a possible upside of 1,306.4% from the stock's current price.
View analysts' price targets for Corbus Pharmaceuticals
.

Are investors shorting Corbus Pharmaceuticals?

Corbus Pharmaceuticals saw a increase in short interest in the month of August. As of August 14th, there was short interest totaling 15,500,000 shares, an increase of 11.0% from the July 30th total of 13,970,000 shares. Based on an average daily volume of 1,620,000 shares, the short-interest ratio is presently 9.6 days.
View Corbus Pharmaceuticals' Short Interest
.

Who are some of Corbus Pharmaceuticals' key competitors?

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO), Canopy Growth (CGC) and KushCo (KSHB).

Who are Corbus Pharmaceuticals' key executives?

Corbus Pharmaceuticals' management team includes the following people:
  • Dr. Yuval Cohen, CEO & Director (Age 45, Pay $810.55k)
  • Mr. Sean F. Moran CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 62, Pay $520k)
  • Dr. Barbara White, Head of Research & Chief Medical Officer (Age 70, Pay $570.7k)
  • Dr. Robert Paul Discordia Ph.D., Chief Operating Officer (Age 56)
  • Ted Jenkins, Sr. Director of Investor Relations & Communications

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.37%), Point72 Asset Management L.P. (1.84%), Pinnacle Associates Ltd. (1.47%), Nuveen Asset Management LLC (0.94%), Tekla Capital Management LLC (0.46%) and Russell Investments Group Ltd. (0.43%). Company insiders that own Corbus Pharmaceuticals stock include Barbara White, Craig Stuart Millian, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran and Yuval Cohen.
View institutional ownership trends for Corbus Pharmaceuticals
.

Which major investors are selling Corbus Pharmaceuticals stock?

CRBP stock was sold by a variety of institutional investors in the last quarter, including AdvisorShares Investments LLC, Raymond James Financial Services Advisors Inc., Virtus ETF Advisers LLC, Pinnacle Associates Ltd., Aries Wealth Management, Sawtooth Solutions LLC, AE Wealth Management LLC, and Bank of Montreal Can.
View insider buying and selling activity for Corbus Pharmaceuticals
.

Which major investors are buying Corbus Pharmaceuticals stock?

CRBP stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Nuveen Asset Management LLC, Tekla Capital Management LLC, Swiss National Bank, UBS Group AG, PDT Partners LLC, SG Americas Securities LLC, and Jacobs Levy Equity Management Inc.. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Barbara White, Craig Stuart Millian, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran, and Yuval Cohen.
View insider buying and selling activity for Corbus Pharmaceuticals
.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $1.90.

How big of a company is Corbus Pharmaceuticals?

Corbus Pharmaceuticals has a market capitalization of $155.25 million and generates $36.14 million in revenue each year. The biopharmaceutical company earns $-71,450,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Corbus Pharmaceuticals employs 141 workers across the globe.

What is Corbus Pharmaceuticals' official website?

The official website for Corbus Pharmaceuticals is www.corbuspharma.com.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.